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Background: MicroRNAs (miRNAs) are small, non-coding RNAs (20–24 nucleotides) that post-transcriptionally
modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs.
The aim of this study was to investigate the expression pattern of microRNA-26b (miR-26b) in human breast cancer,
and its potential role in disease pathogenesis.
Methods: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to determine the
expression level of miR-26b in 38 breast cancer specimens and adjacent normal breast tissues. MTT assays were
conducted to explore the impact of miR-26b overexpression on the proliferation of human MDA-MB-231 breast
cancer cells. Luciferase reporter assays were employed to validate regulation of a putative target of miR-26b. The
effect of modulating miR-26b on endogenous levels of this target were subsequently confirmed via qRT-PCR and
Western blot.
Results: MiR-26b expression was relatively decreased in breast cancer specimens compared with adjacent normal
tissues (P<0.01). Overexpression of miR-26b suppressed MDA-MB-231 cell growth. Luciferase assays using a reporter
carrying a putative miR-26b target site in the 3' untranslated region of PTGS2 revealed that miR-26b directly targets
PTGS2. Overexpression of miR-26b led to downregulation of PTGS2 at the mRNA and protein level, as assessed by
qRT-PCR and Western blot. Targeted knockdown of PTGS2 by siRNA significantly inhibited the proliferation of
MDA-MB-231 breast cancer cells.
Conclusions: MiR-26b may act as a tumor suppressor in breast cancer. The overexpression of miR-26b inhibits
cellular growth by targeting PTGS2, suggesting its use as a potential therapeutic target for breast cancer.
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MicroRNAs are a class of small, non-coding RNAs, which
are capable of regulating gene expression at the post-
transcriptional level. Mechanistically, miRNAs function by
binding to the 30 untranslated regions (UTRs) of target
mRNAs, causing translation to be blocked and/or mRNA
degradation [1]. MicroRNAs play diverse roles in tumori-
genesis and in the progression of breast cancer, and may
act as oncogenes, tumor suppressors and modulators of
tumor proliferation, invasion, apoptosis and therapy resist-
ance [2-6]. An increasing body of evidence indicates that
miR-26b is downregulated in hepatocellular carcinoma [7],
nasopharyngeal carcinoma [8], primary squamous cell lung* Correspondence: fendou000@foxmail.com
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reproduction in any medium, provided the orcarcinoma [9], squamous cell carcinoma of the tongue [10]
and in breast cancer [11]. Furthermore, overexpression
of miR-26b induces apoptosis in MCF-7 breast cancer
cells by targeting SLC7A11 [11]. However, to date,
the role of miR-26b in breast cancer tumorigenesis is
incompletely understood.
Prostaglandin-endoperoxide synthase-2 (PTGS2) encodes
the COX-2 enzyme, which catalyzes the conversion of
arachidonic acid to prostaglandins (PGs) and other
eicosanoids. PTGS2 expression, which is undetectable in
most normal tissues, is induced in response to hypoxia,
inflammatory cytokines, tumor promoters, growth factors
and other stressors [12,13]. PTGS2 is involved in carcino-
genesis, immune response suppression, inhibition of apop-
tosis, angiogenesis and tumor cell invasion and metastasis.
Recent studies have indicated that PTGS2 genetic variationhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 miR-26b inhibits the proliferation of breast
cancer cells.
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Furthermore, overexpression of PTGS2 in patients with
breast cancer is associated with a worse prognosis [16].
Several studies have demonstrated the involvement of
miRNAs in the regulation of PTGS2. MiR-199a and miR-
101a are implicated in PTGS2 regulation during embryo
implantation [17]. Furthermore, miR-26b has been shown
to directly silence PTGS2 and regulate PTGS2 expression
in desferrioxamine (DFOM)-treated carcinoma of nasopha-
ryngeal epithelial (CNE) cells [8].
In this study, we report that miR-26b expression is
significantly decreased in human breast cancer, and its
overexpression inhibits the proliferation of MDA-MB-231
cells by targeting PTGS2. These results indicate that
miR-26b functions as a tumor suppressor, whose dysregulation
may be involved in the initiation and development of
human breast cancer.
Results
Expression of miR-26b is decreased in human breast
cancer
To investigate the involvement of miR-26b in breast cancer
development, we analyzed levels of miR-26b in 38 invasive
ductal breast cancer tissues and associated normal adjacent
tissues (NATs) by quantitative reverse transcription-
polymerase chain reaction (qRT-PCR). MiR-26b expression
was significantly decreased in breast cancer tissues
compared with NATs (7.3 fold, P<0.01) (Figure 1).
Suppression of breast cancer proliferation by miR-26b
To investigate the effect of miR-26b on breast cancer
cell proliferation, miR-26b mimics were transfected into
the human breast cancer cell line, MDA-MB-231 and
proliferation was assessed by MTT assay. As shown in
Figure 2, cellular proliferation gradually declined following
transfection with miR-26b, in a concentration-dependentFigure 1 miR-26b is relatively downregulated in breast cancer.manner. Treatment of cells with 50 nM miR-26b led to a
decrease in MDA-MB-231 cell growth at 72 h (7%) and
96 h (18%) (P<0.05) compared with the negative control.
This inhibitory effect was significantly enhanced following
transfection with 100 nM miR-26b at 48 h (14%), 72 h
(29%) and 96 h (28%) (P<0.05) compared with the negative
control. Taken together, these results demonstrate that
miR-26b inhibits the proliferation of MDA-MB-231 breast
cancer cells.MiR-26b regulates PTGS2 expression in breast cancer cells
To investigate the downstream targets of miR-26b that may
play a role in mediating this growth suppressive effect, we
searched for putative targets using the miRanda database.
We identified a binding site for miR-26b in the 30-UTR of
PTGS2 mRNA. To validate miR-26b binding to this
predicted site, we cloned the 30-UTR of PTGS2 containing
the putative miR-26b binding site into a luciferase reporter
construct, in addition to a mutated PTGS2 30-UTR
(Figure 3A). Luciferase activity was significantly decreased
following co-transfection of psiCHECK-2/PTGS2 30-UTR
with miR-26b, compared with the miR-negative control
(miR-NC) (Figure 3B). Furthermore, luciferase activity was
also decreased following co-transfection of psiCHECK-2
/PTGS2 30-UTR mutant and miR-26b (Figure 3B). These
results indicate that miR-26b specifically binds to the
30-UTR of PTGS2. The effect of miR-26b transfection
on endogenous PTGS2 mRNA and protein expression
was subsequently evaluated in MDA-MB-231 cells by
qRT-PCR and Western blot. As shown in Figure 3C
and 3D, the expression of PTGS2 mRNA and protein
was decreased in MDA-MB-231 cells transfected with
100 nM miR-26b mimics compared with the control.
These results suggest that miR-26b directly targets
PTGS2 in breast cancer cells.
Figure 3 PTGS2 is a direct target of miR-26b in breast cancer.
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Since overexpression of miR-26b suppressed the
proliferation of MDA-MB-231 breast cancer cells, and
given that PTGS2 is a direct target of miR-26b, we
hypothesized that the inhibitory effect of miR-26b on breast
cancer cell viability might be achieved via targeting PTGS2.
To investigate this, we assessed the effect of targeted
knockdown of PTGS2 on MDA-MB-231 cell growth by
MTT assay. Treatment of cells with 50 nmol/L PTGS2
siRNA markedly suppressed cell viability by 21%, 34% and
41% at 48 h, 72 h and 96 h, respectively, compared with
control siRNA (P<0.01) (Figure 4). This suggests thatFigure 4 knockdown of PTGS2 significantly supresses the proliferatioPTGS2 promotes the proliferation of breast cancer cells
in vitro. These results demonstrate that downregulation of
PTGS2 expression by miR-26b contributes, at least
in part, to the suppression of the growth of breast
cancer cells.
Discussion
The discovery of the first miRNA, lin-4, in Caenorhabditis
elegans initiated a new era of miRNA biology. Since then,
thousands of miRNAs have been identified and annotated.
Furthermore, an increasing body of evidence indicates that
miRNAs are differentially expressed between normal and
tumor tissues, suggesting that dysregulation of miRNAn of breast cancer cells.
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In this study, we performed qRT-PCR to investigate the
expression pattern of miR-26b in primary human
breast cancer. MiR-26b expression was significantly
downregulated in breast cancer specimens compared
with normal tissue. Similar findings have been reported
in several other cancer types, including hepatocellular
carcinoma [7], nasopharyngeal carcinoma [8], primary
squamous cell lung carcinoma [9], squamous cell carcin-
oma of tongue [10] and glioma [23]. Consistent with this
study, Xiao-Xiao Liu et al. reported that miR-26b expres-
sion is downregulated in MCF7, HCC1937, MDA-MB-231,
MDA-MB-468, MDA-MB-453, BT-549 and BT-474 breast
cancer cell lines compared with CCD-1095Sk normal
breast skin cells [11]. These results indicate that miR-26b
is downregulated in human breast cancer specimens and
cell lines.
It is well established that regulation of gene expression
by miRNAs plays a role in the development, differentiation,
proliferation, apoptosis, invasion and metastasis of a variety
of cancers. In our study, transfection of miR-26b mimics
into MDA-MB-231 cells led to a significant decrease in
cellular proliferation, indicating that miR-26b represses
the growth of breast cancer cells. Previous studies
demonstrated that overexpression of miR-26b in DFOM-
treated CNE cells inhibited proliferation via degradation
of PTGS2 mRNA and suppression of PTGS2 protein
translation [8]. Gain- and loss-of-function studies showed
that miR-26b and its host genes CTDSP1/2/L cooperate
to block G1/S-phase progression by activating pRb protein
in hepatocellular carcinoma [24]. MiR-26b is also involved
in processes governing apoptosis in breast cancer. Previous
studies reported that miR-26b mimics triggered apoptosis
of human breast cancer MCF7 cells, and SLC7A11 was
identified as a direct target of miR-26b [11]. In glioma,
low levels of miR-26b were inversely correlated with
tumor grade. Ectopic expression of miR-26b inhibited
the proliferation, migration and invasion of human
glioma cells, possibly via regulation of its downstream
target, EphA2 [23]. Taken together, these studies indicate
that dysregulated expression of miR-26b may affect
multiple cancers.
Computational algorithms revealed that the 30-UTR of
PTGS2 contains a binding site for miR-26b. To confirm
targeting of PTGS2 by miR-26b, we integrated a
fragment of the PTGS2 30-UTR containing the target
sequence, or a fragment whose target site was mutated,
into a luciferase reporter vector. Luciferase activity was
significantly repressed in cells transfected with the con-
struct harboring the miR-26b target sequence compared
with the mutated control vector. Both PTGS2 mRNA and
protein levels decreased after transfection of MDA-MB-231
cells with miR-26b, as shown in Figure 3C and 3D.
These data indicate that miR-26b directly interacts withPTGS2 mRNA and represses PTGS2 protein expression.
Furthermore, silencing PTGS2 expression by siRNA led
to inhibition of cellular proliferation. In conclusion, these
findings support the hypothesis that decreased expression
of PTGS2 by miR-26b accounts for the suppression of
cellular proliferation in breast cancer.
Conclusions
Taken together, we demonstrate that miR-26b is
downregulated in breast cancer specimens compared
with normal tissue. MiR-26b directly downregulates
PTGS2 and inhibits breast cancer cell proliferation.
These data indicate that miR-26b may serve as a tumor
suppressor gene involved in breast cancer pathogenesis.
Materials and methods
Specimens
In this study, 38 paired breast cancer and normal
specimens were collected from the Department of Breast
and Thyroid Surgery of Shanghai Tenth People’s Hospital,
Shanghai, China. All samples were confirmed as invasive,
ductal breast cancer by trained pathologists. No patients
received chemotherapy or radiotherapy prior to surgery.
Cell culture
The MDA-MB-231 breast cancer cell line was purchased
from the Chinese Science Institute. Cells were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Gibco, USA) supplemented with 10% Fetal Bovine
Serum (FBS) (Gibco), penicillin (100 units/ml) and
streptomycin (100 μg/ml) (Enpromise, China). Cells
were incubated at 37°C in a humidified chamber
supplemented with 5% CO2.
qRT-PCR
For detection of miR-26b expression, primer design and
qRT-PCR was performed as previously described [25].
MiRNA was isolated using the miRcute miRNA isolation
kit according to the manufacturer’s instructions (Tiangen,
China). MiR-26b was amplified using the following primers:
50-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA
CTGGATACGACGAGCCA-30 (stem-loop primer), 50-CG
CCCTGTTCTCCATTACTT-30 (sense) and 50-CCAGTGC
AGGGTCCGAGGT-30 (antisense). Amplification of
control U6 small nuclear RNA was performed using
the following primers: 50-GTCCTATCCAGTGCAGGGT
CCGAGGTGCACTGGATACGACAAAATATGGAAC-30
(stem-loop primer), 50-TGCGGGTGCTCGCTTCGCAGC
-30 (sense) and 50-CCAGTGCAGGGTCCGAGGT-30
(antisense). cDNA was generated by reverse transcription
using the PrimeScript™ RT-PCR kit in accordance with
manufacturer’s instructions (Takara, Japan). Real-time
PCR was performed on a 7900HT fast RT-PCR instrument
(Applied Biosystems, Singapore). PCR parameters for
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followed by 40 cycles of 30 s at 95°C and 45 s at 60°C.
For quantification of PTGS2 mRNA expression, total
RNA was isolated using TRIzol (Invitrogen, USA), and
cDNA was generated by reverse transcription using the
PrimeScript RT-PCR kit in accordance with the
manufacturer’s instructions (Takara). Real-time PCR
was performed on a 7900HT fast RT-PCR instrument
using SYBR-Green and the following primers: PTGS2,
50-CCTGTGCCTGATGATTGC-30 (sense), 50-CTGATGC
GTGAAGTGCTG-30 (antisense); β-actin, 50-AGCAGCAT
CGCCCCAAAGTT-30 (sense) and 50-GGGCACGAAGGC
TCATCATT-30 (antisense). The PCR parameters for
relative quantification were as follows: 2 min at 95°C,
followed by 40 cycles of 15 s at 95°C and 30 s at 60°C.
Each sample was tested in triplicate. The relative expression
was calculated using the relative quantification equation
(RQ) = 2-.Delta;ΔCT [26].
Western blot analysis
Protein samples were separated by 12% SDS-
polyacrylamide gel (SDS-PAGE) and transferred onto
PVDF membranes (Beyotime, China). Immune complexes
were formed by incubation of membranes with primary
antibody (BioVision, USA) overnight at 4°C. Blots were
washed and incubated for 1 h with HRP-conjugated anti-
rabbit secondary antibody. Immunoreactive protein bands
were detected using an Odyssey Scanning system.
MTT assay
MDA-MB-231 cells (5000/well) were plated in 96-well
plates (BD Biosciences, USA) and incubated at 37°C
overnight. The next day, sub-confluent (50-60%) cells
were transfected with miR-26b mimics (50 nmol/L
and 100 nmol/L) or PTGS2 siRNA (50 nmol/L)
(Genepharma, China) using Lipofectamine 2000
(Invitrogen, USA), in accordance with the manufacturer’s
instructions. MiR-NC and siRNA control were used as
negative controls. DMEM medium was replaced with
DMEM supplemented with 10% FBS 5 h post-transfection
with miR-26b mimics or PTGS2 siRNA. Cell proliferation
was assessed at 24, 48, 72 and 96 h, using the MTT
proliferation assay kit in accordance with the manufacturer’s
instructions (Sigma, USA). All experiments were performed
in biological triplicate.
Luciferase assay
The 30 untranslated region (30 UTR) of PTGS2 containing
the predicted miR-26b binding site was amplified by PCR
in a total volume of 50 μl using the Primer star kit (Takara)
in accordance with the manufacturer’s instructions. The
primers used were 50-TAGGCGATCGCTCGAGCTGT
TGCGGAGAAAGGAGTC-30 (sense); 50-AATTCCC
GGGCTCGAGTAGTTACTTCTAATGCATCATGG-30(antisense). The mutant constructs were generated by mu-
tation. Fragments were subcloned into the Xho I site in the
30-UTR of Renilla luciferase of the psiCHECK-2 reporter
vector. psiCHECK-2/PTGS2 30-UTR or psiCHECK-2
/PTGS-2 30-UTR mutant reporter plasmids (200 ng) were
co-transfected with miR-26b mimics or miR-NC (100 nM)
into MDA-MB-231 cells (60% confluence) using
Lipofectamine 2000 (Invitrogen), in accordance with the
manufacturer’s instructions. After 48 h, cells were lysed and
reporter activity was assessed using the Dual-luciferase re-
porter assay system (Promega, USA) in accordance with
the manufacturer’s protocols. Renilla luciferase activity was
normalized to firefly luciferase activity.
Statistical analysis
Data are presented as the mean ± standard deviation
from at least three independent experiments. The two-
tailed t-test was used to draw a comparison between
groups. The null hypothesis was rejected at the 0.05 level.
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